Alemtuzumab for B-cell chronic lymphocytic leukemia

References

• Redaelli A, Laskin BL, Stephens JM et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care13, 279–287 (2004).
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R. Young patients with chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia. Molecular Genetics, Biology, Diagnosis, and Management. GB Faguet (Ed.). Humana Press Inc, Totova, NJ, USA 401–413 (2004).
   Google Scholar
• Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N. Engl. J. Med.338, 1506–1514 (1998).
   PubMed Web of Science ®Google Scholar
• CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukaemia: a meta-analysis of the randomized trials. J. Natl. Cancer Inst.91, 861–868 (1999).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood87, 4990–4997 (1996).
   PubMed Web of Science ®Google Scholar
• Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia16, 1015–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Nicolle A, Proctor SJ, Summerfield GP. High dose chlorambucil in the treatment of lymphoid malignancies. Leuk. Lymphoma 2004, 45, 271–275 (2004).
   PubMed Web of Science ®Google Scholar
• Jaksic B, Briugatelli M, Krc I et al. High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy. Vienna. Cancer79, 2107–2114 (1997).
   PubMed Web of Science ®Google Scholar
• Summerfield GP, Taylor PR, Mounter PJ, Proctor SJ. High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin’s lymphoma. Br. J. Haematol.116, 781–786 (2002).
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med.343, 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood96, 2723–2729 (2000).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med. Sci. Monit.11, 71–79 (2005).
   Google Scholar
• Johnson S, Smith AG, Löffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL. Lancet347, 1432–1438 (1996).
   PubMed Web of Science ®Google Scholar
• Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood98, 2319–2325 (2001).
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood107, 885–891 (2006).
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol.25, 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood108, 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet370, 230–239 (2007).
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk. Lymphoma45, 205–219 (2004).
   PubMed Web of Science ®Google Scholar
• Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene26, 3644–3653 (2007).
   PubMed Web of Science ®Google Scholar
• Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs58, 79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs9, 9–22 (2005).
   Google Scholar
• Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood101, 2507–2513 (2003).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin. Oncol.29(1 Suppl. 2), 70–74 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol.19, 2165–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol.19, 2153–2164 (2001).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol.23, 4079–4088 (2005).
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood100, 3115–3120 (2002).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood101, 6–14 (2003).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood105, 49–53 (2005).
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide and rituximab as initial therapy of chric lymphocytic leukemia. Blood (2008) (In press).
   Google Scholar
• Wierda W, O’Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol.23, 4070–4078 (2005).
   PubMed Web of Science ®Google Scholar
• Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide, and rituximab is an active, well – tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol.24, 1575–1581 (2006).
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood109, 405–411 (2007).
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Blonski JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur. J. Haematol.79, 107–113 (2007).
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Keating MJ. Novel immune – based treatment strategies for chronic lymphocytic leukemia. J. Clin. Oncol.23, 6325–6332 (2005).
   PubMed Web of Science ®Google Scholar
• Robak T. Novel monoclonal antibodies for chronic lymphocytic leukemia. Curr. Cancer Drug Targets8, 156–171 (2008).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Moller Pedersen L et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A Phase I-II study. Blood111, 1094–1100 (2008).
   PubMed Web of Science ®Google Scholar
• Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood111, 1594–1602 (2008).
   PubMed Web of Science ®Google Scholar
• Byrd JC, O’Brien S, Flinn I et al. Safety and efficacy results from a Phase I trial of single agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic eukemia. Blood104( Suppl. 1), 686a (2004) (Abstract 2503).
   Web of Science ®Google Scholar
• Byrd JC, O’Brien SO, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res.13, 4448–4455 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien S, Byrd J, Kipps TJ et al. Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL). J. Clin. Oncol.108(Suppl. 1 ) (2006) (Abstract 6597).
   Google Scholar
• Byrd JC, Castro J, O’Brien S et al. Comparison results from a Phase 1 /2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood108(Suppl. 1 ), 14a (2006) (Abstract 32).
   Web of Science ®Google Scholar
• Carnahan J, Stein R, Qu Z et al. Epratunuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol.44, 1331–1341 (2007).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab humanized anti-CD22 antibody in indolent non-Hodgkin’s lymphoma. J. Clin. Oncol.21, 3051–3059 (2003).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti-CD22 antibody,in aggressive non-Hodgkin’s lymphoma. Phase I/II clinical trial results. Clin. Cancer Res.10, 5327–5334 (2004).
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Anasetti C, Santos ES. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol. Blood Marrow Transplant.13, 373–385 (2007).
   PubMed Web of Science ®Google Scholar
• Gribben JG. Salvage therapy for CLL and the role of stem cell transplantation. In: Hematology. American Society of Hematology Education Book. American Society of Hematology, DC, USA 292–298 (2005).
   Google Scholar
• Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia21, 12–17 (2007).
   PubMed Web of Science ®Google Scholar
• Rawandi E, O’Brien S. Alemtuzumab. Expert Rev. Anticancer Ther.5, 39–51 (2005).
   PubMed Web of Science ®Google Scholar
• Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs63, 1229–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martins M, Matutes E et al. Levels of expression of C52 in normal and leukemic B cells; correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22, 185–191 (1988).
   Google Scholar
• Hederer RA, Guntermann C, Miller N et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52) – induced TCR-dependent signal transduction in human T cells. Int. Immunol.12, 505–516 (2000).
   PubMed Web of Science ®Google Scholar
• Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res.22, 185–191 (1998).
   PubMed Web of Science ®Google Scholar
• Quigley MM, Bethel KJ, Sharpe RW et al. CD52 expression in hairy cell leukemia. Am. J. Hematol.74, 227–230 (2003).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Masuyama J, Sohma Y et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin. Immunol.120, 247–259 (2006).
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki A, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for patients requiring treatment for chronic lymphocytic leukemia. J. Clin. Oncol.25, 5616–5623 (2007).
   PubMed Web of Science ®Google Scholar
• Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist13, 167–174 (2008).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutré S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol.20, 205–213 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenblum MD, LaBelle JL, Chang CC et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood103, 1969–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Hale G. Alemtuzumab in stem cell transplantation. Med.Oncol.19(Suppl.), S33–S47 (2002).
   Google Scholar
• Reichman LM, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature332, 323–331 (1988).
   PubMed Web of Science ®Google Scholar
• Cheetham GMT, Hale G, Waldmann H, Bloomer AC. Crystal structure of rat anti-CD52 (Campath-1) therapeutic antibody. Fab fragment and its humanized counterpart. J. Mol. Biol.284, 85–89 (1998).
   PubMed Web of Science ®Google Scholar
• Page MJ, Sydenham MA. 19 A structure of the therapeutic antibody Campath-1H lab in complex with a synthetic peptide antigen. J. Mol. Biol.289, 293–301 (1999).
   PubMed Web of Science ®Google Scholar
• Page MJ, Sydenham MA. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology9, 64–68 (1991).
   PubMedGoogle Scholar
• Sheeley DM, Merrill BM, Taylor LC. Characterization of monoclonal antibody glycosylation: comparison of terminal a-linked galactose. Analytical Biochem.247, 102–110 (1997).
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood104, 948–955 (2004).
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet340, 748–752 (1992).
   PubMed Web of Science ®Google Scholar
• Tang SC, Hewitt K, Reis MD et al. Immunosuppressive toxicity of Campath-1H monoclonal antibody in the patients with recurrent low grade lymphoma. Leuk. Lymphoma24, 93–101 (1996).
   PubMed Web of Science ®Google Scholar
• Rebello P, Hale G. Pharmacokinetics of Campath-1H: assay development and validation. J. Immunol. Method.260, 285–302 (2002).
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br. J. Clin. Pharmacol.64, 278–291 (2007).
   PubMed Web of Science ®Google Scholar
• Nabhan C, Dyer MJ, Rosen ST. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology17, 253–262 (2003).
   PubMedGoogle Scholar
• Montillo M, Cafro AM, Tedeschi A et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica87, 695–700 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy patients with chronic lymphocytic leukemia. Cancer98, 2657–2663 (2003).
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Miqueleiz S et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol.24, 2337–2342 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Wierda WG, LaPushin R et al. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine refractory chronic lymphocytic leukemia. Eur. J. Haematol.80, 296–298 (2008).
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Waldmann H. Efficient complement mediated lysis of cells contaning the Campath-1 (CDw52) antigen. Mol. Immunol.30, 1089–1096 (1993).
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med.6, 443–446 (2000).
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the Campath antibodies. Cytotherapy3, 137–143 (2002).
   Web of Science ®Google Scholar
• Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclasic, caspase- independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol.83, 634–645 (2004).
   PubMed Web of Science ®Google Scholar
• Zent CS, Chen JB, Kurten RC et al. Alemtuzumab (Campath-1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk. Res.28, 495–497 (2004).
   PubMed Web of Science ®Google Scholar
• Smolewski P, Szmigielska-Kaplon A, Cebula B et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma46, 87–100 (2005).
   PubMed Web of Science ®Google Scholar
• Mone AP, Cheney C, Banks AL et al. Alemtuzumab induces caspase independent cell death in human chronic lymphocytic leukemia cells through a lipid raft dependent mechanism. Leukemia20, 272–279 (2006).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. Oncol.15, 1567–1574 (1997).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood99, 3554–3561 (2005).
   Google Scholar
• Rawstron AC, Kennedy B, Moreton P et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood103, 2027–2031 (2004).
   PubMed Web of Science ®Google Scholar
• McCune SL, Gockerman JP, Moore JO et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukaemia. Leuk. Lymphoma43, 1007–1011 (2002).
   PubMed Web of Science ®Google Scholar
• Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood99, 2245–2247 (2002).
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol.23, 7024–7031 (2005).
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O’Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood101, 3413–345 (2003).
   PubMed Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon LI et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk. Lymphoma 2004, 45, 2269–2273.
   PubMed Web of Science ®Google Scholar
• Wierda GW, O’Brien S, Ferrajoli A et al. Salvage therapy with combined cyclophosphamide (C),fludarabine (F),alemtuzumab (A) and rituximab (R) (CFAR) for heavily pretreated patients with CLL. Blood106(Suppl. 1), (2005) (Abstract 719).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukemia. Br. J. Haematol.93(1), 151–153 (1996).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Björkholm M et al. Phase II trial of subcutaneous anti CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood100, 768–773 (2002).
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Fetni R et al. Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (Campath MabCampath) vs chlorambucil as first line therapy for B-cel chronic lymphocytic leukemia (BCLL). Blood108, 592a (2006) (Abstract 2092).
   Google Scholar
• Knauf UW, Lissichkov T, Aldaoud A et al. Bendamustine versus chlorambucil in treatment-naive patients with B-Cell chronic lymphocytic leukemia (B-CLL). Results of an international Phase III study. Blood110, 609a (2007) (Abstract 2043).
   Google Scholar
• Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med.343, 1910–1916 (2000)
   PubMed Web of Science ®Google Scholar
• Grever MR, Lucas DM, Dewald GW et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J. Clin. Oncol.25, 799–804 (2007).
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and delection. Blood103, 3278–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Winkler D, Kröber A et al. Subcutaneous campath-1H (alemtuzumab) in fludarabine refractory CLL: interim analysis of the CLL 2h Study of the German CLL Study Group (GCLLSG). Blood104(Suppl. 1), 140a (Abstract 478) (2004).
   Google Scholar
• Osuji N, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica90, 1435–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev.33, 710–728 (2007).
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur. J. Haematol.72, 79–88 (2004).
   PubMed Web of Science ®Google Scholar
• D’Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia. Endocr. Metab. Immune Disord. Drug Targets8, 62–80 (2008).
   PubMedGoogle Scholar
• Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br. J. Haematol.84, 542–544 (1993).
   PubMed Web of Science ®Google Scholar
• Willis F, Marsh JC, Bevan DH et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol.114, 891–898 (2001).
   PubMed Web of Science ®Google Scholar
• Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia21, 511–514 (2007).
   PubMed Web of Science ®Google Scholar
• Laurenti L, Tarnani M, Efremov DG et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia21, 1819–1821 (2007).
   PubMed Web of Science ®Google Scholar
• Rodon P, Breton P, Courouble G. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukemia with Campath-1H. Eur. J. Haematol.70, 319–321 (2003).
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol.23, 2971–2979 (2005).
   PubMed Web of Science ®Google Scholar
• Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest.23, 488–496(2005).
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia18, 1093–1101 (2004).
   PubMed Web of Science ®Google Scholar
• Schwighofer M, Ritgen B, Eichorst R et al. Consolidation with alemtuzumab improves progression – free survival in patients with chronic lymphocytic leukemia (CLL) in first remission. Long-term follow-up of a randomized phase III trial of the German CLL study group (GCLLSG). Blood108(Suppl. 1), 14a (2006)(Abstract 33).
   Google Scholar
• Fischer K, Schweighpfer CD, Ritgen M et al. Dose escalation study to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD) and safety of alemtuzumab for consolidation therapy in patients with lymphocytic leukemia: phase I i II trial of german CLL Study Group (GCLLSG). Blood110 (2007)(Abstract 2053).
   Web of Science ®Google Scholar
• Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft versus host disease and graft rejection following transplantation of allogenic peripheral blood stem cells. Bone Marrow Transplant26, 69–76 (2000).
   PubMed Web of Science ®Google Scholar
• Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin. Oncol.33(2 Suppl. 5) 536–543 (2006).
   Google Scholar
• Dyer MJ, Kelsey SM, Mackay HJ et al. In vivo “purging” of residual disease in CLL with Campath-1H. Br. J. Haematol.97, 669–672 (1977).
   Google Scholar
• Montillo M, Tedeschi A, Rossi V et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia18, 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R et al.in vivo CAMPATH-1H prevents graft versus host disease following nonmyeloablative stem cell transplantation. Blood96, 2419–2425 (2000).
   PubMed Web of Science ®Google Scholar
• Lush RJ, Haynes AP, Byrne J et al. Allogenic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor lymphocyte infusion. Cytotherapy3, 203–210 (2001).
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL et al. BEAM: alemtuzumab reduced intensity allogenic stem cell transplantation for lymphoproliferative disease, GVHD, toxicity and survival in 65 patients. Blood103, 428–434 (2004).
   PubMed Web of Science ®Google Scholar
• Peggs KS. Role of MabCampath in allogenic transplantation. Ann. Hematol.83(Suppl. 1), S66–S68 (2004).
   Google Scholar
• Carella AM, Beltrami G, Scalzulli PR et al. Alemtuzumab can sucessfuly treat steroid-refractory acute graft-versus-host disease (a GVHD). Bone Marrow Transplant33, 131–132 (2004).
   PubMed Web of Science ®Google Scholar
• Delgado J, Thomson K, Russel N et al. Results of alemtuzumab-based reduced-intensity allogenic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood107, 1724–1730 (2006).
   PubMed Web of Science ®Google Scholar
• Juliusson G, Theorin N, Karlsson K, Frödin U, Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogenic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant37, 503–510 (2006).
   PubMed Web of Science ®Google Scholar
• Keating M, Coutré S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin. Lymphoma4, 220–227 (2004).
   PubMedGoogle Scholar
• Thursky KA, Worth LJ, Seymour JF, Prince H, Slavin MA. Spectrum of infection risk and recomendations for prophylaxis and screening among patients lymphoproliferative disorders treated with alemtuzumab. Br. J. Haematol.132, 3–12 (2006).
   PubMed Web of Science ®Google Scholar
• Lin TS, Flinn IW, Lucas MS et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia19, 1207–1210 (2005).
   PubMed Web of Science ®Google Scholar
• Lundin J, Porwit-MacDonald A, Rossmann ED et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia. Leukemia19, 1207–1210 (2005).
   PubMed Web of Science ®Google Scholar
• O’Brien S, Ravandi F, Riehl T et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood111, 1816–1819 (2008).
   PubMed Web of Science ®Google Scholar
• Lin TS, Donohue KA, Lucas MS et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after rludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB Study 10101. Blood110, 232a (2007) (Abstract 755).
   Google Scholar
• Morrison VA, Bercedis L, Petwrson BL et al. Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based herapy: A comparative analysis of 3 Cancer and Leukemia Group B studies (CALGB 9011, 9712, 19901). Blood110, 233a (2007) (Abstract 756).
   Google Scholar
• Au WY, Leung AYH, Tse EWC et al. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk. Res32(4), 547–551 (2008).
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K et al. Infections complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis.43, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Scott WG, Scott HM. Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukemia. Clin. Drug Investig.27, 755–764 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O’Brien SM, Cortes E et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer98, 773–778 (2003).
   PubMed Web of Science ®Google Scholar
• Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol.20, 3891–3897 (2002).
   PubMed Web of Science ®Google Scholar
• Rai KR, Byrd JC, Peterson B et al. Subcutaneous alemtuzumab following fludarabine for previoysly untreated patients with chronic lymphocytic leukemia(CLL): CALGB Study 19901. Blood102, 676a–677a (2003) (Abstract 2506).
   Web of Science ®Google Scholar
• Dyer MJ, MacKay HJ, Emmett E et al. In vivo purging of residual disease in CLL with Campath-1H. Br. J. Haematol.97, 669–672 (1997).
   PubMed Web of Science ®Google Scholar